>
Switch to:

BridgeBio Pharma Research & Development

: $304.36 Mil (TTM As of Sep. 2020)
View and export this data going back to 2019. Start your Free Trial

This is the expense the company spent on research and development. BridgeBio Pharma's research and development for the three months ended in Sep. 2020 was $92.05 Mil. Its research and development for the trailing twelve months (TTM) ended in Sep. 2020 was $304.36 Mil.


BridgeBio Pharma Research & Development Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

BridgeBio Pharma Annual Data
Dec17 Dec18 Dec19
Research & Development 30.56 140.07 209.95

BridgeBio Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Research & Development Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.28 57.49 68.23 86.60 92.05

BridgeBio Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2020 was 57.485 (Dec. 2019 ) + 68.225 (Mar. 2020 ) + 86.598 (Jun. 2020 ) + 92.05 (Sep. 2020 ) = $304.36 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


BridgeBio Pharma  (NAS:BBIO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


BridgeBio Pharma Research & Development Related Terms


BridgeBio Pharma Research & Development Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)